Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ENYO Pharma

ENYO Pharma
2014 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$47.1M LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of a clinical stage biotechnology platform designed to develop innovative drug candidates by mimicking virus strategies to modulate host cellular functions. The company's platform develops new small molecule therapeutics, mainly first-in-class, in various therapeutic areas with unmet medical needs as well as offers a drug discovery engine based on mimetism of the secular strategy of how viruses have adapted during evolution to hijack the human cellular functions for their own benefits, enabling healthcare givers to access an exhaustive database of all known virus/human protein-protein interactions from which new cellular targets are discovered.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Bâtiment Domilyon
  • 321 avenue Jean Jaurès
  • 69007 Lyon
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ENYO Pharma’s full profile, request a free trial.

ENYO Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 04-Jun-2018 $47.1M 0000 0000 Completed Generating Revenue
3. Grant 06-Dec-2016 00.000 000.00 Completed Startup
2. Early Stage VC (Series A) 03-Feb-2016 $23.9M $23.9M 000.00 Completed Startup
1. Seed Round 01-Jan-2015 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

ENYO Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
To view this company’s complete Cap Table, request access »

ENYO Pharma Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Private Equity-Backed Gaithersburg, MD 000.00 0000000 0000 000.00
00000000 Venture Capital-Backed Sunnyvale, CA 00 00.000 0000000000 00.000
000000 Venture Capital-Backed San Diego, CA 0 00.000 0000000000 0 00.000
0000000 Formerly Angel backed Vancouver, WA 00 000.00 00000000 000.00
0000000 Venture Capital-Backed Farmington, CT 00 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

ENYO Pharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
OrbiMed Venture Capital Minority 000 0000 000000 0
Sofimac Innovation Venture Capital Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

ENYO Pharma Executive Team (11)

Name Title Board
Seat
Contact
Info
Jacky Vonderscher Ph.D Co-Founder, Chief Executive Officer & Board Member
Eric Meldrum Chief Scientific Officer
Laurène Meyniel-Schicklin Co-Founder & Head of Bioinformatics
Benoît de Chassey Ph.D Co-Founder & Head of Drug Discovery Platform
Patrice André Ph.D Co-Founder, Medical Advisor & Board observer

1 Former Executive

You’re viewing 5 of 11 executives. Get the full list »

ENYO Pharma Board Members (17)

Name Representing Role Since Contact
Info
Annette Clancy Self Chairman of the Board 000 0000
Carl Gordon Ph.D OrbiMed Board Observer 000 0000
Chahra Louafi Bpifrance Board Member 000 0000
Francois Thomas Self Board Observer 000 0000
François Thomas MD Self Board Observer 000 0000

1 Former Board Member

You’re viewing 5 of 17 board members. Get the full list »